Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Utility of Circulating Tumour Cells and Plasma microRNA Detection to Predict the Response to Treatment in Patients With Esophageal Adenocarcinoma

NCT02812680 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT02812680
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02812680 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Utility of Circulating Tumour Cells and Plasma microRNA Detection to Predict the Response to Treatment in Patients With Esophageal Adenocarcinoma
Lead sponsor
University Health Network, Toronto
Phase
Observational
Overall status
Completed
Start date
June 30, 2016
Completion date
November 30, 2020
Enrollment
84 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer